Journal of Veterinary Diagnostic Investigation · 1996 · 23 citations · 24 references
Veterinary MedicineInfectious DiseasesVeterinary MicrobiologyAntimicrobial PharmacologyAntimicrobial ResistanceDiagnostic MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingVeterinary Antimicrobial ResistanceVeterinary Antimicrobial TherapyAntimicrobial Susceptibility InterpretationBreakpoints For Veterinary AntimicrobialsDisk Diffusion TestingKinetic Data AnalysisMacrolide TherapyMinimum Inhibitory Concentration DeterminationMinimum Inhibitory Concentration InterpretationMinimum Inhibitory Concentration Testing
Tilmicosin is a novel macrolide antibiotic developed for exclusive use in veterinary medicine. The first tilmicosin-containing product was approved to treat bovine respiratory disease associated with pasteurellae. The development of antimicrobial susceptibility testing guidelines for tilmicosin was predicated on the relationship of clinical efficacy studies that demonstrated a favorable therapeutic outcome, on pharmaco-kinetic data, and on in vitro test data, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS). The NCCLS-approved breakpoints for the MIC dilution testing are resistant > or = 32 micrograms/ml, intermediate 16 micrograms/ml, and susceptible < or = 8 micrograms/ml. The zone of inhibition interpretive criteria for disk diffusion testing with a 15-micrograms disk are resistant < or = 10 mm, intermediate 11-13 mm, and susceptible > or = 14 mm.
24
Ronald P. Gladue, G. Michael Bright, Richard E. Isaacson et al. · Antimicrobial Agents and Chemotherapy · 1989 · 476 citations
Medicine, Immunology, Pharmacology +14
Jeffrey L. Watts, Robert J. Yancey, Sarah A. Salmon et al. · Journal of Clinical Microbiology · 1994 · 94 citations · Full text
Veterinary Medicine, Microbiology, Veterinary Microbiology +17